As of January 2022, at least 60 million individuals are estimated to develop post-acute
sequelae of SARS-CoV-2 (PASC) after infection with severe acute respiratory syndrome …

Although T cells are likely players in severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) immunity, little is known about the phenotypic features of SARS-CoV-2 …

We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell
responses, soluble markers of inflammation, and antibody levels and neutralization capacity …

Many studies have been performed in severe COVID-19 on immune cells in the circulation
and on cells obtained by bronchoalveolar lavage. Most studies have tended to provide …

SARS-CoV-2 has been identified as the causative agent of a global outbreak of respiratory
tract disease (COVID-19). In some patients, the infection results in moderate to severe acute …

Preventing the progression to acute respiratory distress syndrome (ARDS) in COVID-19 is
an unsolved challenge. The involvement of T cell immunity in this exacerbation remains …

Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development,
interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of …

BACKGROUND Patients infected with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) differ in the severity of disease. We hypothesized that characteristics of SARS …

Immune response dynamics in coronavirus disease 2019 (COVID-19) and their severe
manifestations have largely been studied in circulation. Here, we examined the relationship …

The SARS-CoV-2 is responsible for the pandemic COVID-19 in infected individuals, who
can either exhibit mild symptoms or progress towards a life-threatening acute respiratory …